Syneos Health (SYNH) Issues Earnings Results

Syneos Health (NASDAQ:SYNH) issued its earnings results on Thursday, May 9th. The company reported $0.59 EPS for the quarter, topping the Zacks’ consensus estimate of $0.51 by $0.08, MarketWatch Earnings reports. The business had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.09 billion. Syneos Health had a net margin of 0.42% and a return on equity of 9.55%. The company’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period last year, the company posted $0.55 earnings per share. Syneos Health updated its FY 2019 guidance to $3.03-3.23 EPS and its FY19 guidance to $3.03-3.23 EPS.

NASDAQ SYNH opened at $41.23 on Friday. The company has a market cap of $4.28 billion, a PE ratio of 15.74, a price-to-earnings-growth ratio of 1.47 and a beta of 1.36. Syneos Health has a 52-week low of $36.26 and a 52-week high of $56.34. The company has a debt-to-equity ratio of 1.07, a quick ratio of 1.02 and a current ratio of 1.02.

A number of equities analysts have recently commented on the stock. Barclays reaffirmed a “hold” rating and set a $48.00 target price on shares of Syneos Health in a research report on Wednesday, April 17th. ValuEngine downgraded shares of Syneos Health from a “buy” rating to a “hold” rating in a research note on Saturday, April 13th. UBS Group downgraded shares of Syneos Health from a “buy” rating to a “neutral” rating and set a $55.00 price objective on the stock. in a research note on Tuesday, March 19th. Credit Suisse Group increased their price objective on shares of Syneos Health from $49.00 to $51.00 and gave the company an “outperform” rating in a research note on Tuesday, March 19th. Finally, Wolfe Research assumed coverage on shares of Syneos Health in a research note on Tuesday, April 2nd. They set a “market perform” rating on the stock. Six research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $53.33.

Institutional investors and hedge funds have recently made changes to their positions in the business. Loomis Sayles & Co. L P boosted its stake in Syneos Health by 135.8% in the first quarter. Loomis Sayles & Co. L P now owns 500 shares of the company’s stock valued at $26,000 after acquiring an additional 288 shares in the last quarter. Enlightenment Research LLC acquired a new stake in Syneos Health in the fourth quarter valued at approximately $51,000. NumerixS Investment Technologies Inc acquired a new stake in Syneos Health in the fourth quarter valued at approximately $57,000. Bessemer Group Inc. acquired a new stake in Syneos Health in the fourth quarter valued at approximately $59,000. Finally, Rockefeller Capital Management L.P. acquired a new stake in Syneos Health in the first quarter valued at approximately $61,000.

TRADEMARK VIOLATION WARNING: This article was posted by Rockland Register and is the sole property of of Rockland Register. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://rocklandregister.com/2019/06/01/syneos-health-synh-posts-earnings-results.html.

Syneos Health Company Profile

Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.

Recommended Story: What are gap-down stocks?

Earnings History for Syneos Health (NASDAQ:SYNH)

Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.